Fingerprint
Dive into the research topics of 'Corrigendum to ‘Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821–1830] (Annals of Oncology (2019) 30(11) (1821–1830), (S0923753420325904))'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically